Published by Alexander Bueso on 29th April 2020
(Sharecast News) - Shares of US biotechnology outfit Gilead Sciences were halted after the company notified markets that "positive data" were emerging from a clinical trial being conducted by the US government's National Institute of Allergy and Infectious Diseases for the use of its Remdesivir treatment against the Covid-19 coronavirus.